Skip to main content

Advertisement

SpringerLink
Log in

Immunologic therapy for relapsing-remitting multiple sclerosis

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

The treatment of relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis, has been revolutionized in recent years. In addition to effective treatment of acute relapses, therapies are now available to prevent relapses, reduce the burden of disease as seen on magnetic resonance imaging, and possibly even slow the course of disease. There are now several agents either approved, awaiting approval, or in various stages of development in many countries. Evidence suggests that early intervention with these agents will yield the best results in the long run. The current approach to treatment of RRMS is the focus of this discussion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Schumacher GA, Beebe G, Kubler et al.: Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965, 122:522–568.

    Google Scholar 

  2. Poser CM, Paty DW, Sheinberg L, et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227–231.

    Article  PubMed  CAS  Google Scholar 

  3. Thompson AJ, Polman CH, Miller DH, et al.: Primary progressive multiple sclerosis. Brain 1997, 120:1085–1096.

    Article  PubMed  Google Scholar 

  4. Weinshenker BG, Bass GP, Rice G, et al.: The natural history of multiple sclerosis: a geographically based study. Brain 1989, 112:133–146.

    Article  PubMed  Google Scholar 

  5. Broman T, Andersen O, Bergmann L: Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand 1981, 63:6–33.

    PubMed  CAS  Google Scholar 

  6. Confavreux C, Vukusic S, Moreau T, Adeleine P: Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343:1430–1438. This papers suggests a dissociation between progression of disability and relapses.

    Article  PubMed  CAS  Google Scholar 

  7. Sorensen TL, Ransohoff RM: Etiology and pathogenesis of multiple sclerosis. Sem Neurol 1998, 18:287–293.

    CAS  Google Scholar 

  8. Lucchinetti CF, Brueck W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707–717. There is growing evidence that multiple sclerosis may not be a single disease entity. Different clinical courses may be produced by different pathologic mechanisms. Even patients with similar courses may have different pathologies.

    Article  PubMed  CAS  Google Scholar 

  9. Crockard AD, Treacy MT, Droogan AG, et al.: Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis. Mult Scler 1995, 1:20–24.

    PubMed  CAS  Google Scholar 

  10. Miller DH, Thompson AJ, Morrissey SP, et al.: High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neur Neurosurg Psychol 1992, 55:450–453.

    Article  CAS  Google Scholar 

  11. Barkhof R, Tas MW, Frequin ST, et al.: Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994, 36:382–387.

    Article  PubMed  CAS  Google Scholar 

  12. Reder AT, Thapar M, Jensen MA: A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease. Neurology 1994, 44:2289–2294.

    PubMed  CAS  Google Scholar 

  13. Beck RW, Cleary PA, Malcolm M, et al.: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581–588.

    Article  PubMed  CAS  Google Scholar 

  14. Goodkin DE, Kindel RP, Weinstock-Guttman B, et al.: A phase II study of IV methylprednisolone in secondary progressive multiple sclerosis. Neurology 1998, 51:239–245.

    Article  PubMed  CAS  Google Scholar 

  15. Selleberg F, Frederisken JL, Nielsen PM, Olesen J: Double blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998, 51:529–534.

    Google Scholar 

  16. Barnes D, Hughes RA, Morris RW, et al.: Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997, 349:902–906.

    Article  PubMed  CAS  Google Scholar 

  17. Metz LM, Sabuda D, Enns R, et al.: Safety and tolerability of high-dose oral prednisone in the treatment of multiple sclerosis. Neurology 1998, 50:A63.

    Google Scholar 

  18. Weinshenker BG, O’Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878–886. Prior to this publication, it was unknown whether any treatment was of benefit once steroids failed to improve a clinical attack. This evidence provides us with a rational treatment approach to steroidresistant severe attacks.

    Article  PubMed  CAS  Google Scholar 

  19. The INFB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995, 45:1277–1285.

    Google Scholar 

  20. Wee Yong V, Chabot S, Stuve O, Williams G: Interferon beta in the treatment of multiple sclerosis; mechanisms of action. Neurology 1998, 51:682–689.

    Google Scholar 

  21. Kappos L, and the European Study Group on Interferon b-1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491–1497.

    Article  CAS  Google Scholar 

  22. Jacobs LD, Cookfair D, Rudick RA, et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996, 39:285–294.

    Article  PubMed  CAS  Google Scholar 

  23. PRISMS Study Group: Randomised double-blind placebocontrolled study of interferon B-1a in relapsing-remitting multiple sclerosis. Lancet 1998, 352:1498–1504.

    Article  Google Scholar 

  24. Li DK, Paty DW, UBC MS/MRI Analysis Research Group, and PRISMS Study Group: Magnetic resonance imaging results of the PRISMS trial: a randomized, double blind, placebo-controlled study of interferon-B1a in relapsingremitting multiple sclerosis. Ann Neurol 1999, 46:197–206.

    Article  PubMed  CAS  Google Scholar 

  25. Feldmann R, Low-Weiser H, Duschet P, Gschnait F: Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis. Dermatology 1997, 195:52–53.

    Article  PubMed  CAS  Google Scholar 

  26. Monzani F, Caraccio N, Casolaro A, et al.: Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful? Neurology 2000, 55:549–552.

    PubMed  CAS  Google Scholar 

  27. Ross C, Clemmesen KM, Svenson M, et al.: Immunogenicity of interferon-[beta] in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000, 48:706–712.

    Article  PubMed  CAS  Google Scholar 

  28. Johnson KP, Brooks BR, Cohen JA, et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicentre, double blind, placebo-controlled trial. Neurology 1995, 45:1268–1276.

    PubMed  CAS  Google Scholar 

  29. Aharoni R, Teitelbaum D, Sela M, Arnon R: Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 1997, 94:10821–10826.

    Article  PubMed  CAS  Google Scholar 

  30. Aharoni R, Teitelbaum D, Leitner O, et al.: Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A 2000, 97:11472–11477. This interesting paper provides evidence for the purported mechanism of action of glatiramer acetate, at least in an established animal model of experimental allergic encephalitis.

    Article  PubMed  CAS  Google Scholar 

  31. Johnson KP, Brooks BR, Ford CC, et al.: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000, 6:255–266. This study provides evidence of sustained benefit of glatiramer acetate for at least 6 years.

    PubMed  CAS  Google Scholar 

  32. Stangel M, Toyka KV, Gold R: Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 1999, 56:661–663.

    Article  PubMed  CAS  Google Scholar 

  33. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al.: Randomized placebo-controlled trial of monthly intravenous immunoglobulins therapy in relapsing-remitting multiple sclerosis. Lancet 1997, 349:589–593.

    Article  PubMed  CAS  Google Scholar 

  34. Lisak RP: Intravenous immunoglobulins in multiple sclerosis. Neurology 1998, 51(suppl_5):S25-S29.

    PubMed  CAS  Google Scholar 

  35. Yudkin PL, Ellison GW, Ghezzi A, et al.: Overview of azathioprine in multiple sclerosis. Lancet 1991, 338:1051–1055.

    Article  PubMed  CAS  Google Scholar 

  36. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al.: Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995, 37:30–40.

    Article  PubMed  CAS  Google Scholar 

  37. Weinstock-Guttman B, Kinkel RP, Cohen JA, et al.: Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. The Neurologist 1997, 3:178–185.

    Article  Google Scholar 

  38. Oger J, Freedman MS: Consensus statement of the Canadian MS Clinics Network on the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci 1999, 26:274–275.

    PubMed  CAS  Google Scholar 

  39. Rudick RA, Cohen JA, Weinstock-Guttman B, et al.: Management of multiple sclerosis. N Engl J Med 1997, 337:1604–1612.

    Article  PubMed  CAS  Google Scholar 

  40. Paty DW, Hartung HP: Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur J Neurol 1999, 6(suppl 1):S1-S35.

    Google Scholar 

  41. Optic Neuritis Study Group: The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology 1997, 49:1404–1413.

    Google Scholar 

  42. Filippi M, Horsfield MA, Morrissey SP, et al.: Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994, 44:635–641.

    PubMed  CAS  Google Scholar 

  43. Jacobs LD, Beck RW, Simon JH, et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000, 343:898–904. This study, as well as ETOMS (see reference cited in text), supports the early institution of disease-modifying therapy.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Multiple Sclerosis Clinic, University of Ottawa, The Ottawa Hospital-General Campus, 501 Smyth Road, K1H 8L6, Ottawa, Ontario, Canada

    Heather J. MacLean MD, FRCPC & Mark S. Freedman MD, FRCPC

Authors
  1. Heather J. MacLean MD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark S. Freedman MD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

MacLean, H.J., Freedman, M.S. Immunologic therapy for relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep 1, 277–285 (2001). https://doi.org/10.1007/s11910-001-0031-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-001-0031-9

Keywords

Search

Navigation